Showing 4651-4660 of 9330 results for "".
- Valeant to Help Raise Awareness of Domestic Violencehttps://practicaldermatology.com/news/20131002-valeant_to_help_raise_awareness_of_domestic_violence/2459444/Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) is partnering with the National Coalition Against Domestic Violence (NCADV) to help raise awareness of domestic violence. As part of the new domestic violence initiative, Valeant has pledged to donate a portion of sales from all …
- KYTHERA Biopharmaceuticals, Inc. Names F. Michael Ball to Boardhttps://practicaldermatology.com/news/20130925-kythera_biopharmaceuticals_inc_names_f_michael_ball_to_board/2459451/KYTHERA Biopharmaceuticals, Inc. has named F. Michael (Mike) Ball, Chief Executive Officer (CEO) of Hospira, Inc. to its Board of Directors. Mr. Ball brings more than 25 years of healthcare experience to KYTHERA. Mr. Ball was appointed CEO and director of Hospira, a $4 billion company and the world…
- KYTHERA Announces Positive ATX-101 Top Line Phase III Trial Resultshttps://practicaldermatology.com/news/20130925-kythera_announces_positive_atx-101_top_line_phase_iii_trial_results/2459452/KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that its ATX-101 REFINE-1 and REFINE-2 Phase III trials met all primary and secondary endpoints. These two pivotal Phase III trials were conducted in the U.S. and Canada to compare the efficacy and safety of a 2 mg/cm2 dose of ATX-101 …
- Precision Dermatology Names New CEOhttps://practicaldermatology.com/news/20130924-precision_dermatology_names_new_ceo/2459455/Robert J. Moccia has been appointed to the position of Chief Executive Officer at Precision Dermatology Inc. Mr. Moccia has led the introduction of a number of new strategies for growth since joining the company in January of this year. Mr. Moccia has 30 years of experience in dermatology, having m…
- ResurFX for M22 Platform from Lumenis Receives FDA Clearancehttps://practicaldermatology.com/news/20130917-resurfx_for_m22_platform_from_lumenis_receives_fda_clearance/2459459/The FDA recently granted 510(k) clearance for ResurFX, a new fractional non-ablative laser module from Lumenis. ResurFX is the latest application module for the company's M22 platform, expanding its capabilities to perform true fractional non-ablative skin resurfacing. ResurFX uses a 1565 nm fiber…
- GSK Receives FDA Priority Review for Dabrafenib/Trametinib Combination in Metastatic Melanomahttps://practicaldermatology.com/news/20130916-gsk_receives_priority_review_from_fda_for_dabrafenibtrametinib_combination_in_metastatic_melanoma/2459460/The FDA has granted priority review designation to GlaxoSmithKline's supplemental New Drug Applications (sNDAs) for combined use of Tafinlar (dabrafenib) and Mekinist (trametinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 E or K mutation. The FD…
- Exuviance Launches Age Less Everyday Daily Moisturizerhttps://practicaldermatology.com/news/20130912-exuviance_launches_age_less_everydaydaily_moisturizer/2459462/NeoStrata Company, Inc., recently introduced Exuviance Age Less Everyday, a daily moisturizer formulated to correct the signs of aging for skin that is dry, sensitive, or easily impacted by everyday stressors. Exuviance Age Less Everyday is formulated with a PHA + Bionic complex that gently stimul…
- FDA Approves Botox Cosmetic to Treat Crow's Feet Lines in Adultshttps://practicaldermatology.com/news/20130912-fda_approves_botox_cosmetic_to_treat_crows_feet_lines_in_adults/2459463/The FDA recently approved Botox Cosmetic (onabotulinumtoxinA) for an additional indication to temporarily treat moderate to severe lateral canthal lines. Allergan's Botox Cosmetic was first approved in the United States in 2002 for the temporary improvement of moderate to severe gl…
- Phase I Trial for Implantable Melanoma Vaccine Beginshttps://practicaldermatology.com/news/20130910-phase_i_trial_for_implantable_melanoma_vaccine_begins/2459466/A cross-disciplinary team of scientists, engineers, and clinicians recently announced the start of a phase I clinical trial of an implantable vaccine to treat melanoma. The effort is the fruit of a new model of translational research being pursued at the Wyss Institute for Bio…
- Novan Awarded Contract by BARDA to Develop a Medical Countermeasure for Thermal Burnshttps://practicaldermatology.com/news/20130829-novan_awarded_contract_by_barda_to_develop_a_medical_countermeasure_for_thermal_burns/2459472/The US Department of Health and Human Services has entered into a contract with Novan to advance the development of a nitric oxide-based therapy as a topical treatment for thermal burns. The Biomedical Advanced Research and Development Authority (BARDA), an agency within the O…